In ZINC since | Heavy atoms | Benign functionality |
---|---|---|
October 3rd, 2005 | 11 | No |
Popular Name: Dopamine hydrochloride Dopamine hydrochloride
Find On: PubMed — Wikipedia — Google
CAS Numbers: 203633-19-6 , 51-61-6 , 62-31-7 , 62-31-7, 51-61-6 , 62-31-7, 51-61-6 [dopamine] , 645-31-8 , [51-61-6] , [62-31-7]
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride (1:1)
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-dihydroxyphenyl)ethan-1-aminium; dopamine; dopaminium cation
2-(3,4-Dihydroxyphenyl)ethyl-1,1,2,2-D4-amine hydrochloride
2-(3,4-dihydroxyphenyl)ethylamine
2-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
3,4-Dihydroxyphenethylamine hydrochloride
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrobromide
3-Hydroxytyramine hydrochloride
3-Hydroxytyramine hydrochloride, 99%
3-HYDROXYTYRAMINE HYDROCHLORIDE; CPD000059081; Dopamine hydrochloride; Intropin; SAM002554938
3-Hydroxytyraminehydrochloride
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-aminoethyl)benzene-1,2-diol
4-(2-aminoethyl)benzene-1,2-diol hydrobromide
4-(2-Aminoethyl)benzene-1,2-diol hydrochloride
4-(2-Aminoethyl)pyrocatechol hydrochloride
51-61-6; D07870; Dopamine (INN); Medopa (TN)
62-31-7; Actopamin (TN); D00633; Dopamine hydrochloride (JP16/USP); Intropin (TN)
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL 279, Cardiosteril, Dopamine Fresenius, Dopastat, Intropin, Rascordin, Revivan, Tensamin
CHEBI:11695; CHEBI:43686; CHEBI:14203; CHEBI:11930; CHEBI:23886; CHEBI:1764
CPD000059081; Intropin; SAM002554938
Dopamine (USAN)(*hydrochloride*)
Dopamine hydrochloride (Inotropin)
m-Hydroxytyramine hydrochloride
Pyrocatechol, 4-(2-aminoethyl)-
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Type pH range | xlogP | Des A‑Pol Apolar desolvation (kcal/mol) | Des Pol Polar desolvation (kcal/mol) | H Don H-bond donors | H Acc H-bond acceptors | Chg Net charge | tPSA (Ų) | MWT Molecular weight (g/mol) | RB Rotatable bonds | DL |
---|---|---|---|---|---|---|---|---|---|---|
Ref Reference (pH 7) | -0.05 | -1.62 | -50.24 | 5 | 3 | 1 | 68 | 154.189 | 2 | ↓ |
Note Type | Comments | Provided By |
---|---|---|
MP | 218 - 220 | Enamine Building Blocks |
MP | 218...220 | Enamine Building Blocks |
Mp [°C] | 241 - 243 | Acros Organics |
Melting_Point | 243-250? | Alfa-Aesar |
Melting_Point | 243-250° | Alfa-Aesar |
UniProt Database Links | 5H1AA_TAKRU; 5H1AB_TAKRU; 5HT1A_CANFA; 5HT1A_GORGO; 5HT1A_HORSE; 5HT1A_HUMAN; 5HT1A_MOUSE; 5HT1A_PANTR; 5HT1A_PONPY; 5HT1A_RAT; 5HT1A_VULVU; 5HT1A_XENLA; 5HT1B_CANFA; 5HT1B_CAVPO; 5HT1B_CRIGR; 5HT1B_DIDVI; 5HT1B_FELCA; 5HT1B_GORGO; 5HT1B_HORSE; 5HT1B_HUMA | ChEBI |
ALOGPS_SOLUBILITY | 7.43e+00 g/l | DrugBank-approved |
purity | 9.500000000000000e+001 | Enamine Building Blocks Enamine Building Blocks |
Purity | 95% | Fluorochem |
Purity | 98% | Fluorochem |
therap | cardiotonic, antihypotensive | MicroSource Spectrum |
Purity | CP98 | APIChem |
Target | Dopamine Receptor | Selleck Chemicals |
Therapy | Endogenous neurotransmitter | SMDC MicroSource |
Patent Database Links | EP0771800; EP0771801; EP0900568; EP0924205; EP0940401; EP0953567; EP0974363; EP1051980; EP1065205; EP1070715; EP1082289; EP1088550; EP1099438; EP1108430; EP1136071; EP1177792; EP1207159; EP1251128; EP1254661; EP1256343; EP1256578; EP1325917; EP1364957; EP | ChEBI |
PUBCHEM_SUBSTANCE_COMMENT | NCC_SAMPLE_SUPPLIER : LightBiologicals; NCC_SUPPLIER_STRUCTURE_ID : H-5381; NCC_SUPPLIER_SAMPLE_COMMENTS : WHITE POWDER; 1 hydrogen chloride | NIH Clinical Collection via PubChem |
Indications | neurotransmitter | KeyOrganics Bioactives |
Reactome Database Links | REACT_15372; REACT_15382; REACT_15468; REACT_15485; REACT_15517; REACT_15524; REACT_15531; REACT_15533; REACT_15538; REACT_16959; REACT_17008; REACT_17033; REACT_20519; REACT_22188; REACT_22221; REACT_22234; REACT_22239; REACT_22268; REACT_22283; REACT_22 | ChEBI |
S phrase | S24/25: Avoid contact with skin and eyes. | Acros Organics |
PUBCHEM_SUBSTANCE_COMMENT | SAMPLE_SUPPLIER: LightBiologicals; SUPPLIER_STRUCTURE_ID: H-5381; SALT: 1 hydrogen chloride; SUPPLIER_COMMENTS: WHITE POWDER | NIH Clinical Collection via PubChem |
PUBCHEM_PATENT_ID | WO1996018395A1; WO1998031362A1; WO2000006162A1; WO2000066537A1; WO2000077238A1 | IBM Patent Data |
MP | ~240° | Fluorochem |
Code | Description | Organism Class | Affinity (nM) | LE (kcal/mol/atom) | Type |
---|---|---|---|---|---|
ADA1B-1-E | Alpha-1b Adrenergic Receptor (cluster #1 Of 4), Eukaryotic | Eukaryotes | 61 | 0.92 | Binding ≤ 10μM |
ADA2A-3-E | Alpha-2a Adrenergic Receptor (cluster #3 Of 4), Eukaryotic | Eukaryotes | 61 | 0.92 | Binding ≤ 10μM |
ADA2B-4-E | Alpha-2b Adrenergic Receptor (cluster #4 Of 4), Eukaryotic | Eukaryotes | 61 | 0.92 | Binding ≤ 10μM |
ADA2C-3-E | Alpha-2c Adrenergic Receptor (cluster #3 Of 4), Eukaryotic | Eukaryotes | 61 | 0.92 | Binding ≤ 10μM |
ADCY2-2-E | Adenylate Cyclase Type II (cluster #2 Of 2), Eukaryotic | Eukaryotes | 5000 | 0.67 | Binding ≤ 10μM |
ADCY3-2-E | Adenylate Cyclase Type III (cluster #2 Of 2), Eukaryotic | Eukaryotes | 5000 | 0.67 | Binding ≤ 10μM |
ADCY4-2-E | Adenylate Cyclase Type IV (cluster #2 Of 2), Eukaryotic | Eukaryotes | 5000 | 0.67 | Binding ≤ 10μM |
ADCY5-2-E | Adenylate Cyclase Type V (cluster #2 Of 2), Eukaryotic | Eukaryotes | 5000 | 0.67 | Binding ≤ 10μM |
ADCY6-2-E | Adenylate Cyclase Type VI (cluster #2 Of 2), Eukaryotic | Eukaryotes | 5000 | 0.67 | Binding ≤ 10μM |
ADCY8-1-E | Adenylate Cyclase Type VIII (cluster #1 Of 2), Eukaryotic | Eukaryotes | 5000 | 0.67 | Binding ≤ 10μM |
ADRB1-2-E | Beta-1 Adrenergic Receptor (cluster #2 Of 2), Eukaryotic | Eukaryotes | 10000 | 0.64 | Binding ≤ 10μM |
D4A3N4-1-E | Brain Adenylate Cyclase 1 (cluster #1 Of 1), Eukaryotic | Eukaryotes | 3500 | 0.69 | Binding ≤ 10μM |
DRD1-1-E | Dopamine D1 Receptor (cluster #1 Of 4), Eukaryotic | Eukaryotes | 7 | 1.04 | Binding ≤ 10μM |
DRD3-1-E | Dopamine D3 Receptor (cluster #1 Of 2), Eukaryotic | Eukaryotes | 9 | 1.02 | Binding ≤ 10μM |
DRD4-2-E | Dopamine D4 Receptor (cluster #2 Of 4), Eukaryotic | Eukaryotes | 5340 | 0.67 | Binding ≤ 10μM |
DRD5-1-E | Dopamine D5 Receptor (cluster #1 Of 1), Eukaryotic | Eukaryotes | 5340 | 0.67 | Binding ≤ 10μM |
MTR1A-2-E | Melatonin Receptor 1A (cluster #2 Of 2), Eukaryotic | Eukaryotes | 7100 | 0.66 | Binding ≤ 10μM |
MTR1B-2-E | Melatonin Receptor 1B (cluster #2 Of 2), Eukaryotic | Eukaryotes | 9100 | 0.64 | Binding ≤ 10μM |
OPRD-1-E | Delta Opioid Receptor (cluster #1 Of 3), Eukaryotic | Eukaryotes | 3045 | 0.70 | Binding ≤ 10μM |
OPRK-2-E | Kappa Opioid Receptor (cluster #2 Of 6), Eukaryotic | Eukaryotes | 3045 | 0.70 | Binding ≤ 10μM |
OPRM-1-E | Mu-type Opioid Receptor (cluster #1 Of 4), Eukaryotic | Eukaryotes | 3045 | 0.70 | Binding ≤ 10μM |
Q8CFM9-1-E | Adenylate Cyclase Type VII (cluster #1 Of 1), Eukaryotic | Eukaryotes | 3500 | 0.69 | Binding ≤ 10μM |
Q9WTR4-2-E | Norepinephrine Transporter (cluster #2 Of 2), Eukaryotic | Eukaryotes | 7 | 1.04 | Binding ≤ 10μM |
SC6A3-3-E | Dopamine Transporter (cluster #3 Of 3), Eukaryotic | Eukaryotes | 6400 | 0.66 | Binding ≤ 10μM |
SGMR1-4-E | Sigma Opioid Receptor (cluster #4 Of 6), Eukaryotic | Eukaryotes | 3045 | 0.70 | Binding ≤ 10μM |
ARP19-1-E | Cyclic AMP Phosphoprotein (cluster #1 Of 1), Eukaryotic | Eukaryotes | 3500 | 0.69 | Functional ≤ 10μM |
DRD1-1-E | Dopamine D1 Receptor (cluster #1 Of 1), Eukaryotic | Eukaryotes | 35 | 0.95 | Functional ≤ 10μM |
DRD2-1-E | Dopamine D2 Receptor (cluster #1 Of 1), Eukaryotic | Eukaryotes | 5 | 1.06 | Functional ≤ 10μM |
DRD4-1-E | Dopamine D4 Receptor (cluster #1 Of 1), Eukaryotic | Eukaryotes | 2 | 1.11 | Functional ≤ 10μM |
DRD2-3-E | Dopamine D2 Receptor (cluster #3 Of 24), Eukaryotic | Eukaryotes | 843 | 0.77 | Binding ≤ 10μM |
Z50597-1-O | Rattus Norvegicus (cluster #1 Of 5), Other | Other | 29 | 0.96 | Binding ≤ 10μM |
Z50425-11-O | Plasmodium Falciparum (cluster #11 Of 22), Other | Other | 10000 | 0.64 | Functional ≤ 10μM |
Z50512-1-O | Cavia Porcellus (cluster #1 Of 7), Other | Other | 1700 | 0.73 | Functional ≤ 10μM |
Z50592-3-O | Oryctolagus Cuniculus (cluster #3 Of 8), Other | Other | 76 | 0.91 | Functional ≤ 10μM |
Z50594-6-O | Mus Musculus (cluster #6 Of 9), Other | Other | 10000 | 0.64 | Functional ≤ 10μM |
Z50597-12-O | Rattus Norvegicus (cluster #12 Of 12), Other | Other | 5268 | 0.67 | Functional ≤ 10μM |
Uniprot | Swissprot | Description | Affinity (nM) | LE (kcal/mol/atom) | Type |
---|---|---|---|---|---|
ADA1B_RAT | P15823 | Alpha-1b Adrenergic Receptor, Rat | 61 | 0.92 | Binding ≤ 1μM |
ADA2A_RAT | P22909 | Alpha-2a Adrenergic Receptor, Rat | 58 | 0.92 | Binding ≤ 1μM |
ADA2B_RAT | P19328 | Alpha-2b Adrenergic Receptor, Rat | 58 | 0.92 | Binding ≤ 1μM |
ADA2C_RAT | P22086 | Alpha-2c Adrenergic Receptor, Rat | 58 | 0.92 | Binding ≤ 1μM |
DRD1_RAT | P18901 | Dopamine D1 Receptor, Rat | 150 | 0.87 | Binding ≤ 1μM |
DRD1_HUMAN | P21728 | Dopamine D1 Receptor, Human | 100 | 0.89 | Binding ≤ 1μM |
DRD1_BOVIN | Q95136 | Dopamine D1 Receptor, Bovin | 200 | 0.85 | Binding ≤ 1μM |
DRD2_BOVIN | P20288 | Dopamine D2 Receptor, Bovin | 1.8 | 1.11 | Binding ≤ 1μM |
DRD2_RAT | P61169 | Dopamine D2 Receptor, Rat | 1.1 | 1.14 | Binding ≤ 1μM |
DRD2_HUMAN | P14416 | Dopamine D2 Receptor, Human | 1.89 | 1.11 | Binding ≤ 1μM |
DRD3_HUMAN | P35462 | Dopamine D3 Receptor, Human | 13.2 | 1.00 | Binding ≤ 1μM |
DRD3_RAT | P19020 | Dopamine D3 Receptor, Rat | 11 | 1.01 | Binding ≤ 1μM |
DRD4_RAT | P30729 | Dopamine D4 Receptor, Rat | 2 | 1.11 | Binding ≤ 1μM |
DRD4_HUMAN | P21917 | Dopamine D4 Receptor, Human | 1.2 | 1.14 | Binding ≤ 1μM |
DRD5_RAT | P25115 | Dopamine D5 Receptor, Rat | 2 | 1.11 | Binding ≤ 1μM |
DRD5_HUMAN | P21918 | Dopamine D5 Receptor, Human | 15 | 1.00 | Binding ≤ 1μM |
SC6A3_RAT | P23977 | Dopamine Transporter, Rat | 200 | 0.85 | Binding ≤ 1μM |
Q9WTR4_RAT | Q9WTR4 | Norepinephrine Transporter, Rat | 6.63 | 1.04 | Binding ≤ 1μM |
Z50597 | Z50597 | Rattus Norvegicus | 2 | 1.11 | Binding ≤ 1μM |
ADCY2_RAT | P26769 | Adenylate Cyclase Type II, Rat | 3500 | 0.69 | Binding ≤ 10μM |
ADCY3_RAT | P21932 | Adenylate Cyclase Type III, Rat | 3500 | 0.69 | Binding ≤ 10μM |
ADCY4_RAT | P26770 | Adenylate Cyclase Type IV, Rat | 3500 | 0.69 | Binding ≤ 10μM |
ADCY5_RAT | Q04400 | Adenylate Cyclase Type V, Rat | 3500 | 0.69 | Binding ≤ 10μM |
ADCY6_RAT | Q03343 | Adenylate Cyclase Type VI, Rat | 3500 | 0.69 | Binding ≤ 10μM |
Q8CFM9_RAT | Q8CFM9 | Adenylate Cyclase Type VII, Rat | 3500 | 0.69 | Binding ≤ 10μM |
ADCY8_RAT | P40146 | Adenylate Cyclase Type VIII, Rat | 3500 | 0.69 | Binding ≤ 10μM |
ADA1B_RAT | P15823 | Alpha-1b Adrenergic Receptor, Rat | 61 | 0.92 | Binding ≤ 10μM |
ADA2A_RAT | P22909 | Alpha-2a Adrenergic Receptor, Rat | 58 | 0.92 | Binding ≤ 10μM |
ADA2B_RAT | P19328 | Alpha-2b Adrenergic Receptor, Rat | 58 | 0.92 | Binding ≤ 10μM |
ADA2C_RAT | P22086 | Alpha-2c Adrenergic Receptor, Rat | 58 | 0.92 | Binding ≤ 10μM |
ADRB1_RAT | P18090 | Beta-1 Adrenergic Receptor, Rat | 10000 | 0.64 | Binding ≤ 10μM |
D4A3N4_RAT | D4A3N4 | Brain Adenylate Cyclase 1, Rat | 3500 | 0.69 | Binding ≤ 10μM |
OPRD_RAT | P33533 | Delta Opioid Receptor, Rat | 3045 | 0.70 | Binding ≤ 10μM |
DRD1_HUMAN | P21728 | Dopamine D1 Receptor, Human | 100 | 0.89 | Binding ≤ 10μM |
DRD1_RAT | P18901 | Dopamine D1 Receptor, Rat | 150 | 0.87 | Binding ≤ 10μM |
DRD1_BOVIN | Q95136 | Dopamine D1 Receptor, Bovin | 1600 | 0.74 | Binding ≤ 10μM |
DRD2_BOVIN | P20288 | Dopamine D2 Receptor, Bovin | 1.8 | 1.11 | Binding ≤ 10μM |
DRD2_RAT | P61169 | Dopamine D2 Receptor, Rat | 1.1 | 1.14 | Binding ≤ 10μM |
DRD2_HUMAN | P14416 | Dopamine D2 Receptor, Human | 1.89 | 1.11 | Binding ≤ 10μM |
DRD3_RAT | P19020 | Dopamine D3 Receptor, Rat | 11 | 1.01 | Binding ≤ 10μM |
DRD3_HUMAN | P35462 | Dopamine D3 Receptor, Human | 13.2 | 1.00 | Binding ≤ 10μM |
DRD4_RAT | P30729 | Dopamine D4 Receptor, Rat | 2 | 1.11 | Binding ≤ 10μM |
DRD4_HUMAN | P21917 | Dopamine D4 Receptor, Human | 1.2 | 1.14 | Binding ≤ 10μM |
DRD5_RAT | P25115 | Dopamine D5 Receptor, Rat | 2 | 1.11 | Binding ≤ 10μM |
DRD5_HUMAN | P21918 | Dopamine D5 Receptor, Human | 15 | 1.00 | Binding ≤ 10μM |
SC6A3_HUMAN | Q01959 | Dopamine Transporter, Human | 6400 | 0.66 | Binding ≤ 10μM |
SC6A3_RAT | P23977 | Dopamine Transporter, Rat | 200 | 0.85 | Binding ≤ 10μM |
OPRK_RAT | P34975 | Kappa Opioid Receptor, Rat | 3045 | 0.70 | Binding ≤ 10μM |
MTR1A_HUMAN | P48039 | Melatonin Receptor 1A, Human | 7100 | 0.66 | Binding ≤ 10μM |
MTR1B_HUMAN | P49286 | Melatonin Receptor 1B, Human | 9100 | 0.64 | Binding ≤ 10μM |
OPRM_RAT | P33535 | Mu Opioid Receptor, Rat | 3045 | 0.70 | Binding ≤ 10μM |
Q9WTR4_RAT | Q9WTR4 | Norepinephrine Transporter, Rat | 6.63 | 1.04 | Binding ≤ 10μM |
Z50597 | Z50597 | Rattus Norvegicus | 2 | 1.11 | Binding ≤ 10μM |
SGMR1_RAT | Q9R0C9 | Sigma Opioid Receptor, Rat | 3045 | 0.70 | Binding ≤ 10μM |
Z50512 | Z50512 | Cavia Porcellus | 1500 | 0.74 | Functional ≤ 10μM |
ARP19_RAT | Q712U5 | Cyclic AMP Phosphoprotein, Rat | 3500 | 0.69 | Functional ≤ 10μM |
DRD1_HUMAN | P21728 | Dopamine D1 Receptor, Human | 37 | 0.95 | Functional ≤ 10μM |
DRD1_RAT | P18901 | Dopamine D1 Receptor, Rat | 3500 | 0.69 | Functional ≤ 10μM |
DRD2_RAT | P61169 | Dopamine D2 Receptor, Rat | 1.1 | 1.14 | Functional ≤ 10μM |
DRD2_HUMAN | P14416 | Dopamine D2 Receptor, Human | 0.1 | 1.27 | Functional ≤ 10μM |
DRD4_RAT | P30729 | Dopamine D4 Receptor, Rat | 2.4 | 1.10 | Functional ≤ 10μM |
DRD4_HUMAN | P21917 | Dopamine D4 Receptor, Human | 10 | 1.02 | Functional ≤ 10μM |
Z50594 | Z50594 | Mus Musculus | 10000 | 0.64 | Functional ≤ 10μM |
Z50592 | Z50592 | Oryctolagus Cuniculus | 38 | 0.94 | Functional ≤ 10μM |
Z50425 | Z50425 | Plasmodium Falciparum | 10000 | 0.64 | Functional ≤ 10μM |
Z50597 | Z50597 | Rattus Norvegicus | 1437 | 0.74 | Functional ≤ 10μM |
Description | Species |
---|---|
Catecholamine biosynthesis | |
Cytosolic sulfonation of small molecules | |
Dopamine clearance from the synaptic cleft | |
Dopamine Neurotransmitter Release Cycle | |
Dopamine receptors | |
Enzymatic degradation of dopamine by COMT | |
Enzymatic degradation of Dopamine by monoamine oxidase | |
G alpha (i) signalling events | |
G alpha (s) signalling events | |
Na+/Cl- dependent neurotransmitter transporters | |
Norepinephrine Neurotransmitter Release Cycle | |
Organic cation transport | |
Transport of nucleosides and free purine and pyrimidine bases across the plasma |
Description | Species |
---|---|
Adenylate cyclase activating pathway | |
Adenylate cyclase inhibitory pathway | |
Adrenaline signalling through Alpha-2 adrenergic receptor | |
Adrenaline,noradrenaline inhibits insulin secretion | |
Adrenoceptors | |
Class A/1 (Rhodopsin-like receptors) | |
CREB phosphorylation through the activation of Adenylate Cyclase | |
Dopamine clearance from the synaptic cleft | |
Dopamine receptors | |
G alpha (i) signalling events | |
G alpha (s) signalling events | |
G alpha (z) signalling events | |
G-protein activation | |
Glucagon signaling in metabolic regulation | |
MASTL Facilitates Mitotic Progression | |
Na+/Cl- dependent neurotransmitter transporters | |
Opioid Signalling | |
Peptide ligand-binding receptors | |
PKA activation | |
PKA activation in glucagon signalling | |
Vasopressin regulates renal water homeostasis via Aquaporins |